ZNF648 and coronary artery disorder: In the present pharmacogenetic study of rosuvastatin effects in CAD patients, associations between both TC (and/or LDL-C) and CIMT changes during the same follow-up period (6 or 12 months) were observed for the polymorphisms rs55730499 of LPA (after 12 months of therapy) and rs1689800 of ZNF648 (after 6 months of therapy).